Lieberman Miriam R, Liebman Tracey N, Alapati Usha, Khachemoune Amor
SUNY Downstate Medical Center.
Dermatol Online J. 2014 Dec 13;21(2):13030/qt18r2916d.
Anti-tumor necrosis factor induced lupus (ATIL) is a rare side effect reported in patients treated with anti-tumor necrosis factor medications such as infliximab, etanercept and adalimumab. Of the three, this condition has been least commonly reported secondary to adalimumab. In this report, we present a case of ATIL in a patient treated for rheumatoid arthritis (RA) with adalimumab. This report will increase physician awareness of the warning signs, diagnostic options and potential complications of ATIL. In this patient, adalimumab was discontinued and treatment was started, leading to improvement in the patient's status.
抗肿瘤坏死因子诱导的狼疮（ATIL）是在用英夫利昔单抗、依那西普和阿达木单抗等抗肿瘤坏死因子药物治疗的患者中报告的一种罕见副作用。在这三种药物中，继发于阿达木单抗的这种情况报告得最少。在本报告中，我们介绍了一例在用阿达木单抗治疗类风湿性关节炎（RA）的患者中发生ATIL的病例。本报告将提高医生对ATIL的警示信号、诊断选项和潜在并发症的认识。在该患者中，停用了阿达木单抗并开始治疗，使患者状况得到改善。
